Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.44 |
| ▸ | TTBK2 | Q6IQ55 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13213035 | 0.87 | PAK4 (0.48) | TTBK1TTBK2EGFRAURKAAURKB | |
| SCHEMBL3030226 | 0.85 | PIK3CG (0.46) | TTBK1TTBK2EGFRAURKBPIK3CA | |
| SCHEMBL3032817 | 0.81 | BRAF (0.39) | ACP1JAK1 | |
| SCHEMBL3029601 | 0.80 | PTK2 (0.42) | ACP1 | |
| SCHEMBL13213029 | 0.79 | AXL (0.44) | ACP1JAK1 | |
| SCHEMBL3029507 | 0.79 | PDK1 (0.43) | — | |
| SCHEMBL13213027 | 0.77 | TTBK1 (0.58) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL29426202 | 0.77 | TTBK1 (0.58) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL2062260 | 0.76 | BCL6 (0.42) | EGFRACP1JAK1 | |
| SCHEMBL20119696 | 0.75 | TTBK1 (0.51) | TTBK1TTBK2EGFRAURKBABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393814-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SuperGen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | AXL, FLT3, TYRO3 | TTBK1 391/4885TTBK2 475/4885EGFR 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.